Back to blog

AstraZeneca Changes U.S. Exchange: What Does It Mean for European Investors?

At the beginning of the week, shares of pharmaceutical giant AstraZeneca rose by 1.5%* on the London Stock Exchange. The reason? It was a reaction to the planned transfer of trading from Nasdaq via American Depositary Receipts directly to the New York Stock Exchange (NYSE). In response, investors in Europe began to wonder: “What would such a move mean for my portfolio?”

AstraZeneca Changes U.S. Exchange: What Does It Mean for European Investors?

Harmonization

Chairman Michel Demare emphasized in an official statement that the new harmonized listing model is primarily intended to support the company’s long-term strategy of sustainable growth and access to global investors. The statement further noted that AstraZeneca remains firmly anchored in the United Kingdom—with its headquarters, tax residency, and primary listings in London and Stockholm. It can therefore be said that the transfer within the United States does not mean an escape from London but rather the company’s effort to expand its international investor base.

azn_ln

Source: Trading Economics*

London Under Pressure

The moves of major companies, however, evoke a broader trend. In recent years, London has faced a significant outflow of prestigious names—Unilever moved its activities to Amsterdam, while Glencore and Ashtead are considering similar steps. This is why news of a possible departure of AstraZeneca from London was perceived with concern. Based on current information, however, these concerns have been partially alleviated, though it is also clear that competition between stock exchanges is tougher than ever.

Political Dimension

The traditional political pressure from the U.S. is also not negligible. President Donald Trump repeatedly warned pharmaceutical companies that if they do not increase investment and production in the United States, they could face high tariffs. The move to list on the NYSE can therefore also be seen as a diplomatic gesture—a way to stay closer to U.S. investors and regulators without the company losing its European identity.

In addition, at the beginning of September the company decided to cancel its planned £200 million expansion of its research center in Cambridge, which at the same time signals that even in the United Kingdom the business environment is not without problems.

What Comes Next?

From a European investor’s perspective, AstraZeneca’s move to the NYSE is primarily about practical consequences. Expanding access to U.S. capital can support the company’s long-term growth, which may also be reflected in the performance of its shares on the London Stock Exchange. At the same time, however, this step is a reminder that London is no longer an automatic center for global companies, and the competitive pressure from the U.S. and the EU will continue to increase over time.[1]

*Past performance is not a guarantee of future results.

[1] Forward-looking statements represent assumptions and current expectations, which may not be accurate, or are based on the current economic environment, which may change. These statements do not guarantee future performance. By their nature, forward-looking statements involve risk and uncertainty, as they relate to future events and circumstances that cannot be predicted, and actual developments and results may differ materially from those expressed or implied in any forward-looking statements.

Disclaimer! This marketing material is not and must not be understood as investment advice. Past performance is not a guarantee of future results. Investing in foreign currency may affect returns due to fluctuations. All securities transactions may result in both profits and losses. Forward-looking statements represent assumptions and current expectations, which may not be accurate, or are based on the current economic environment, which may change. These statements do not guarantee future performance. CAPITAL MARKETS, o.c.p., a.s. is an entity regulated by the National Bank of Slovakia.

Sources:

https://www.investing.com/news/stock-market-news/astrazeneca-to-list-directly-on-nyse-while-keeping-uk-listing-shares-up-4259703
https://www.theguardian.com/business/2025/sep/29/astrazeneca-plans-new-york-stock-exchange-listing-but-isnt-quitting-london

Read more

Micron Continues Last Year’s Trend: What Is Driving the Growth of This Giant?

Micron Continues Last Year’s Trend: What Is Driving the Growth of This Giant?

Shares of Micron Technology have gained approximately 27% since the beginning of the year*. This sharp rise can be defined as a direct reaction to signals from the broader semiconductor ecosystem, particularly following strong quarterly results from TSMC, which confirmed that investments in AI infrastructure are far from over. As one of the few key manufacturers of memory and storage solutions, Micron stands at the very center of the technological transformation. But will this growth continue into 2026?
European Defense Strategy as a Renewed Investment Pillar

European Defense Strategy as a Renewed Investment Pillar

Defense spending in the European Union has definitively shifted in recent years from the margins of political and investment interest to the center of attention. A combination of persistent geopolitical threats, the armed conflict in Ukraine, growing doubts about the long-term security commitments of the United States toward NATO, and a historical investment deficit is creating an environment in which Europe has no alternative but to significantly strengthen its own defense capabilities. Which companies are likely to benefit the most?
SpaceX Heads for the Stock Market in 2026: Potentially the Largest IPO in Market History

SpaceX Heads for the Stock Market in 2026: Potentially the Largest IPO in Market History

After years of speculation, SpaceX’s stock market debut is beginning to look like a reality. Elon Musk, the company’s founder and current CEO, confirmed that reports about a planned IPO are true, with the market already factoring in a potential valuation of up to USD 1.5 trillion. If these estimates materialize, SpaceX would surpass Saudi Aramco’s 2019 IPO record and go down in history as the largest public offering ever. [1]
Micron and the RAM crisis at the end of 2025: How AI is turning memory into a key component

Micron and the RAM crisis at the end of 2025: How AI is turning memory into a key component

The memory market at the end of 2025 faces an enormous hardware challenge, as AI infrastructure creates demand that spreads through the entire chain. As a result, component costs in the under-$200 phone segment have risen by 20 to 30% since the beginning of 2025. Experts warn that smartphone prices may rise by tens of percent. Micron has already indicated that the market tension is expected to persist in 2026 as well, which is exactly why memory prices and availability are being addressed worldwide.